Castration-resistant prostate cancer: descriptive yet pejorative?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed.

1. The undesirable resilience of the pejorative term "castrate-resistant prostate cancer".Irish journal of medical science · 2022
   Article
2. HMGB1 promotes tumor progression and invasion through HMGB1/TNFR1/NF-κB axis in castration-resistant prostate cancer.American journal of cancer research · 2021
   Article
3. PRKAR2B plays an oncogenic role in the castration-resistant prostate cancer.Oncotarget · 2017
   Article
4. Current and emerging therapies for bone metastatic castration-resistant prostate cancer.Cancer control : journal of the Moffitt Cancer Center · 2015
   Review
5. c-Jun NH2-terminal kinase-induced proteasomal degradation of c-FLIPL/S and Bcl2 sensitize prostate cancer cells to Fas- and mitochondria-mediated apoptosis by tetrandrine.Biochemical pharmacology · 2014
   Article
6. Mechanisms of Androgen-Independent Prostate Cancer.EJIFCC · 2014
   Article
7. Inhibition of hedgehog and androgen receptor signaling pathways produced synergistic suppression of castration-resistant prostate cancer progression.Molecular cancer research : MCR · 2013
   Article
8. Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression.Molecular & cellular proteomics : MCP · 2013
   Article
9. Proteomic profiling of androgen-independent prostate cancer cell lines reveals a role for protein S during the development of high grade and castration-resistant prostate cancer.The Journal of biological chemistry · 2012
   Article
10. Castration-resistant prostate cancer: systemic therapy in 2012.Clinics (Sao Paulo, Brazil) · 2012
    Review

Corrections and comments

• Comment on
  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.2008

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as